The Zynerba RECONNECT study aims to investigate the efficacy of a topical gel in helping with the behavioural issues associated with Fragile X syndrome.  The study is being conducted in several countries including Australia. In Australia the sites are Melbourne, Sydney and Brisbane – with a site in Adelaide due to start soon.

Children who have Fragile X syndrome and are aged between and 3 year and 22 years (extended from 17 to 22 years) are eligible to enrol in the study.
Where families are located outside the cities in which the study is running it is possible that Zynerba may reimburse the costs of travel to the centres.
The study will be enrolling participants until the end of July 2023.
More information:  https://fragilexhelp.com.au/